Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and T… (NCT06523517) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and Type 3
China5 participantsStarted 2024-08-01
Plain-language summary
Primary Objective:
Evaluate the efficacy and safety of eliglustat in Chinese pediatric patients (≥12 to \<18 years old) with Gaucher disease type 1 and type 3.
Secondary Objective:
Evaluate the quality of life in Chinese pediatric patients (≥12 to \<18 years old) with Gaucher disease type 1 and type 3 treated with eliglustat.
Who can participate
Age range
12 Years – 18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Glucocerebrosidase (GBA) activity reduced to ≤30% of the lower limit of normal, or
. GBA activity reduced by \>30% of the lower limit of normal, but confirmed by glucocerebrosidase (GBA) genotype.
. Hemoglobin levels: ≥11.0 g/dL for females and ≥12.0 g/dL for males;
. Platelet count ≥100,000/mm³;
. Spleen volume \<10.0 multiples of normal (MN);
. Liver volume \<1.5 MN.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Changes in hemoglobin level
Timeframe: Baseline, Weeks 13, 26, 39 and 52
2
Changes in platelet count
Timeframe: Baseline, Weeks 13, 26, 39 and 52
3
Changes in spleen volume
Timeframe: Baseline, Weeks 26 and 52
4
Changes in liver volume
Timeframe: Baseline, Weeks 26 and 52
5
Changes in Lyso-GL1 level
Timeframe: Baseline, Weeks 13, 26, 39 and 52
6
Skeletal improvement
Timeframe: Baseline, Weeks 26 and 52
7
Assessment of pharmacokinetic (PK) parameter of eliglustat: Cmax
Timeframe: Baseline, Weeks 2, 13, 26 and 52
8
Assessment of pharmacokinetic (PK) parameter of eliglustat: Ctrough